Cytosorbents (CTSO) Cash from Investing Activities (2010 - 2026)
Cytosorbents (CTSO) posted Cash from Investing Activities of -$46000.0 for Q1 2026, up 84.19% on a QoQ basis from -$291000.0 in Q4 2025, and up 2.13% year-over-year from -$45041.7 in Q1 2025.
Cytosorbents (CTSO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Cytosorbents' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$46000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 2.13% year-over-year to -$46000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$414000.0 (up 29.71% YoY) and the FY2025 annual result came in at -$415000.0, up 37.97% from the prior year.
- Cash from Investing Activities was -$46000.0 for Q1 2026 at Cytosorbents, up from -$291000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $140285.0 in Q2 2023 and bottomed at -$4.7 million in Q2 2022.
- A 5-year average of -$501283.1 and a median of -$135922.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 375.79% — and 2025, when it jumped 118.39%.
- Cytosorbents' Cash from Investing Activities stood at -$206080.0 in 2022, then jumped by 34.04% to -$135922.0 in 2023, then gained by 8.77% to -$124000.0 in 2024, then sank by 134.68% to -$291000.0 in 2025, then soared by 84.19% to -$46000.0 in 2026.
- Business Quant data shows CTSO's Cash from Investing Activities at -$46000.0 in Q1 2026, -$291000.0 in Q4 2025, and $55000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.82 Bn | 176.53 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.59 Bn | 67.14 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.11 Bn | 25.82 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.28 Bn | 21.15 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Cytosorbents | 22.51 Mn | 17.71 Mn | 6.13 Mn | -46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46,000.00 |
| Mar 31, 2026 | -46,000.00 |
| Dec 31, 2025 | -291,000.00 |
| Dec 31, 2025 | -291,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | -132,000.00 |
| Jun 30, 2025 | -132,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Sep 30, 2024 | -299,000.00 |
| Sep 30, 2024 | -299,000.00 |
| Jun 30, 2024 | -118,982.00 |
| Jun 30, 2024 | -118,982.00 |
| Mar 31, 2024 | -127,018.00 |
| Mar 31, 2024 | -127,018.00 |
| Dec 31, 2023 | -135,922.00 |
| Dec 31, 2023 | -135,922.00 |